Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D6PMR7
|
|||
| Drug Name |
TAK-755
|
|||
| Synonyms |
ADAMTS13
Click to Show/Hide
|
|||
| Drug Type |
Enzyme replacement
|
|||
| Indication | Congenital thrombotic thrombocytopenic purpura [ICD-11: 3B64.14] | Phase 3 | [1] | |
| Thrombotic thrombocytopenic purpura [ICD-11: 3B64.14; ICD-10: M31.1] | Phase 3 | [2] | ||
| Company |
Takeda
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | A disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13) | Target Info | Replacement | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05770219) Expanded Access Program: TAK-755 (rADAMTS13) for the Prophylaxis and Treatment of Severe Congenital or Hereditary Thrombotic Thrombocytopenic Purpura. U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT03393975) A Phase 3, Prospective, Randomized, Controlled, Open-label, Multicenter, 2 Period Crossover Study With a Single Arm Continuation Evaluating the Safety And Efficacy of BAX 930 (rADAMTS13) in the Prophylactic And On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP]). U.S.National Institutes of Health. | |||
| REF 3 | Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease. Haematologica. 2022 Nov 1;107(11):2650-2660. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.